Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) (vol 43, pg 17, 2020)

被引：1
|
作者：
Patek, Taylor M. [1 ,2 ]
Teng, Chengwen [1 ,2 ]
Kennedy, Kaitlin E. [1 ,2 ]
Alvarez, Carlos A. [3 ]
Frei, Christopher R. [1 ,2 ,4 ,5 ]
机构：
[1] Univ Texas Austin, Pharmacotherapy Div, Coll Pharm, San Antonio, TX USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, Long Sch Med, 7703 Floyd Curl Dr,MSC-6220, San Antonio, TX 78229 USA
[3] Texas Tech Univ, Hlth Sci Ctr, Div Clin Translat Res, Hodge Sch Pharm, Dallas, TX USA
[4] South Texas Vet Hlth Care Syst, San Antonio, TX USA
[5] Univ Hlth Syst, San Antonio, TX USA
来源：
DRUG SAFETY | 2020年 / 43卷 / 08期
关键词：
D O I：
10.1007/s40264-020-00971-y
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
In the original publication of the article, the second sentence in the figure 2 caption should read as below:
引用
收藏
页码：825 / 825
页数：1
相关论文
共 50 条
  • [21] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
    Zhang, Xusheng
    Ren, Xiuli
    Zhu, Tianyu
    Zheng, Wanjin
    Shen, Chengwu
    Lu, Cuicui
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
    Yang, Yang
    Shu, Yamin
    Chen, Guosong
    Yin, Yanchao
    Li, Feie
    Li, Juan
    PLOS ONE, 2022, 17 (12):
  • [23] A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
    Xiaomei Xiong
    Xiuwen Zhang
    Fengmin Tang
    Taomin Huang
    BMC Pharmacology and Toxicology, 26 (1)
  • [24] Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
    Gao, Hui
    Zhai, Xiaohan
    Hu, Yan
    Wu, Hang
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [25] A real-world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS)
    Liu, Hao
    Yan, Wei
    Luo, Di
    Li, Jinsong
    Yan, Dezhi
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [26] Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Sharma, Priyanka
    Gupta, Sheeba Varghese
    Bhatt, Priyanka
    Kandukuru, Abhishek
    Cheng, Feng
    Upadhyay, Gunjan
    Sutariya, Vijaykumar
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (12) : 720 - 728
  • [27] Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)
    Li, Bing
    Chen, Yan
    Zhang, Yongyi
    Qian, Mengying
    Shan, Qing
    Qian, Jiao
    Guo, Jinmin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [28] A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
    Liu, Dan
    Mao, Wei
    Hu, Bin
    Li, Xingxing
    Zhao, Quanfeng
    Zhang, Lin
    Hu, Jing
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Qu, Yaxin
    Wang, Shuxin
    Xie, Hanzhang
    Meng, Xiao
    Cui, Bingnan
    Xiao, Zhanshuo
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [30] Catatonia related to tacrolimus: a real world pharmacovigilance study of FDA adverse event reporting system (FAERS) database
    Yang, Jing
    Yang, Hui
    An, Zhuoling
    EXPERT OPINION ON DRUG SAFETY, 2024,
12345